Cost-effectiveness of consolidation durvalumab for inoperable stage III non-small cell lung cancer in Vietnam.

ABSTRACT:

Background

This study aimed to assess the cost-effectiveness of durvalumab as a treatment option for patients with inoperable stage III non-small cell lung cancer (NSCLC) from healthcare and partial societal perspectives in Vietnam.

Method

A lifetime partitioned survival model was used to evaluate the costs and quality-adjusted life years (QALYs) associated with consolidation durvalumab in comparison with the standard of care alone. Local costs and utilities were incorporated into the model. In the base-case analysis, no discount was applied to the acquisition cost of durvalumab. Scenario-based, one-way and probabilistic-sensitivity analyses were conducted.

Results

The base-case analysis revealed that the intervention resulted in an increase of 1.38 life years or 1.08

SUBMITTER: Mai VQ 

PROVIDER: S-EPMC11407225 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature